Quantcast

New Trial - Combination of BBI608 and BBI503


#1

The following trial may be relevant for synovial sarcoma patients:

https://clinicaltrials.gov/ct2/show/NCT02432326

The 2 drugs have been tried separately but not on sarcoma:

http://meetinglibrary.asco.org/content/135094-144

http://meetinglibrary.asco.org/content/135128-144

The side effects were mostly gastrointestinal. They could be worse in the combination...

These drugs are so called cancer stem cell inhibitors.BBI608 is supposed to inhibit β-catenin, and Nanog pathways in particular. These pathways are active in synovial sarcoma:

http://www.ncbi.nlm.nih.gov/pubmed/20518020

http://www.ncbi.nlm.nih.gov/pubmed/25614489